Authors
Latest:
The Fruits of Comparative EffectivenessNew CER tools grant payers the evidence they need to control drug costs
Latest:
Creating an inner desireTo excel as a competitor, you must be hungry - hungry for success, for results, hungry simply to become the best at what you do.
Latest:
From Conflict to CollaborationNew rules of engagement can help pharma companies to overcome the paralysis of creative conflict.
Latest:
Precision Medicine's March to Market: 'Pairing' for SuccessIn the past few years, we’ve seen the biopharmaceutical industry begin to shift from a one-size-fits-all blockbuster approach toward an individualized, precision science model. This transformation has propelled companion diagnostics (CDx) into playing a more critical role than ever in the commercialization of biopharmaceutical therapeutics.
Latest:
How to make a powerful impact in two minutes or lessSee how you can incorporate these five B's in some of your two-minute-or-less encounters with physicians.
Latest:
Beyond CRM Weaving a Loyalty WebJohn K. loves his new job on the trading floor of the New York Stock Exchange, and the last thing he wants to worry about is testing his blood sugar in the middle of a busy day. But, as a diabetic with high blood pressure, he knows he will feel lightheaded at about 11:45 every work day-just when the trading heats up. His doctor, who wants him to check his blood sugar levels regularly, suggested a monitoring system that allows him to test and record glucose levels without missing a beat.
Latest:
Funnel all selling efforts toward client developmentPrioritize, manage and monitor daily activities.
Latest:
The Ten Billion Dollar MoleculeErythropoietin is marketed by different companies under different names-Epogen, Procrit, Eprex, Espo, Epogin, Aranesp, and NeRecormon-so it has never made anyone's list of best-selling drugs. But EPO is likely to be the first molecule to reach the $10 billon dollar mark in annual sales. Pfizer's Lipitor (atorvastatin) and two biologic proteins, interferon and insulin, will be hot on its heels.
Latest:
Also Known As...The Value of Generic NamesIn the world of pharmaceutical names, the trademark has always been the star, and every other word has played a supporting role. But recent developments at FDA-and the industry's response to those developments-have set the stage for a new approach to nomenclature.
Latest:
Legal: State Compulsory LicensesUnder one bill, states could license patented drugs to generics companies, paying patent holders a royalty.
Latest:
Pfizer Can Mold Its Future by Learning from the PastPfizer Chairman and CEO Hank McKinnell sees the company's $58 billion blockbuster acquisition of Pharmacia as the key to Pfizer's leadership in pharmaceutical markets around the globe.
Latest:
PBMs: Merck-Medco in the Hot SeatFranklin Lakes, New Jersey-Merck’s pharmacy benefit arm, Merck-Medco, is under fire for switching patients to more expensive pharmaceuticals.
Latest:
Thriving Amid UncertaintyAs healthcare struggles to reinvent itself, a confluence of major societal forces has irrevocably changed both the business world and the healthcare landscape.
Latest:
Pediatric MandateFDA's Final Rule Forces the Pharma Industry to Change It's Clinical Trial Culture
Latest:
Focus on the customer to find successReps need to spend time planning, account targeting and learning about new managed care tools that drive today's operations as well as prepare us for tomorrow's growth businesses.
Latest:
Pharma’s Understanding of Competitive IntelligenceDespite the investment in place, industry still struggles to take advantage of competitive intelligence as key decision aid.
Latest:
Establish investment priorities and exploit your 401(k) planA rep's guide to retirement investing.
Latest:
Direct to Consumer: HIV and AdherenceThe flaw lies not in the lack of patient information, but rather in the way they process it.
Latest:
The Sampling SubsidyPhysicians give only 25 percent of samples to newly diagnosed patients, along with a prescription.
Latest:
Manage your resources to drive your businessReps can make a better impact by managing the time they have.
Latest:
Unleash the DragonChina's large patient base and concentrated specialty hospitals make it easier to recruit patients for clinical trials in than in the United States. On average, companies can save from two to five months by conducting a Phase I study in China.
